Eli Lilly’s Retatrutide Outpaces Ozempic on Weight Loss in First Head-to-Head Trial

Eli Lilly and Company (NYSE: LLY) announced that its experimental drug retatrutide helped adults with type 2 diabetes lose more than twice as much weight as Novo Nordisk (NYSE: NVO)‘s Ozempic in the first Phase 3 trial to pit retatrutide against another incretin medicine.

The 80-week TRANSCEND-T2D-2 trial enrolled 1,298 adults whose blood sugar stayed too high despite metformin, taken alone or alongside an SGLT2 inhibitor. Retatrutide patients lost 19.5% of their body weight on the 9 mg dose and 20.9% on the 12 mg dose, or 44.3 lbs and 47.4 lbs. 

Patients on Ozempic 2 mg, the highest approved dose, lost 9.4%, or 20.9 lbs. A1C fell 2.2 points on both retatrutide doses from an average of 8.3%, versus 1.8 points on Ozempic. Lilly said retatrutide also beat Ozempic on cholesterol, triglycerides and blood pressure but did not release those figures.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

Kenneth Custer, executive vice president and president of Lilly Cardiometabolic Health, said retatrutide produced “more than double the weight loss” of Ozempic’s top dose.

Ozempic is approved for type 2 diabetes. Novo sells the same drug, semaglutide, for weight loss as Wegovy, and the trial did not test retatrutide against Wegovy in people with obesity. Lilly is running a separate head-to-head trial, TRIUMPH-5, against its own tirzepatide in that population. In placebo-controlled trials of adults without diabetes, retatrutide 12 mg produced 28.3% weight loss over 80 weeks and Wegovy produced 14.9% over 68 weeks. The populations and trial lengths differ, so the two cannot be compared directly.

The trial was open-label, so patients and doctors knew which drug each person received. Lilly sponsored the study, announced only topline figures and said it will publish detailed results in a peer-reviewed journal.

Diarrhea, the most common side effect, affected 28.3% of patients on 9 mg and 32.7% on 12 mg, against 26.4% on Ozempic, while nausea rates ran close to Ozempic’s. Dysesthesia, an abnormal skin sensation, affected 4.8% on 9 mg and 6.5% on 12 mg, versus 2.7% on Ozempic. Side effects led 4.8% of patients on 9 mg and 7.9% on 12 mg to stop treatment, compared with 2.7% on Ozempic. Lilly described most events as mild to moderate.

Retatrutide has not been approved anywhere, and Lilly says selling it to consumers is illegal. Lilly intends to file for FDA approval as a biologic in the first quarter of 2027. The FDA’s standard goal for a new biologic is 10 months after a 60-day filing period, which points to a decision around early 2028 unless the agency grants priority review. Novo expects an FDA decision on CagriSema, its combination of cagrilintide and semaglutide, by the end of the year.

Information for this briefing was found via the sources and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Goliath Extends Golden Gate Lode 130 Metres With 13.45 g/t Gold Equivalent Over 4.85 Metres

Questcorp Begins 600 Metre Phase 2B Drill Program at La Union

Related News

Denmark’s GDP Gets A Big Boost From Ozempic

National statistics data show that Denmark’s GDP experienced a surge of 1.7% year-on-year during the...

Saturday, September 9, 2023, 11:45:00 AM

Novo Nordisk Shares Surge After Next-Gen Obesity Drug Shows 22% Weight Loss 

Novo Nordisk witnessed a significant uptick in its share price during European trading on Friday...

Sunday, January 26, 2025, 09:16:00 AM

Is Ozempic the New Wonder Drug?

Ozempic has been all the rage lately. It’s become synonymous with weight loss, and lately,...

Monday, May 22, 2023, 03:27:00 PM

$450 Error Nukes Novo Nordisk’s Ozempic Patent, Opening Canada To Generics

Novo Nordisk (NYSE: NVO) has permanently forfeited Canadian patent protection for semaglutide—the blockbuster active ingredient...

Monday, June 16, 2025, 11:38:00 AM

Study Examines Vision Loss Reports in Patients Taking GLP-1 Drugs

A new JAMA study is investigating ophthalmic complications in patients using semaglutide and tirzepatide, the...

Wednesday, February 12, 2025, 02:14:00 PM